Profile of differentially expressed Toll-like receptor signaling genes in the natural killer cells of patients with Sezary syndrome

Imagem de Miniatura
Arquivos
art_MANFRERE_Profile_of_differentially_expressed_Tolllike_receptor_signaling_genes_2017.PDF (2.94 MB)
Citações na Scopus
6
Tipo de produção
article
Data de publicação
2017
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
IMPACT JOURNALS LLC
Autores
Citação
ONCOTARGET, v.8, n.54, p.92183-92194, 2017
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Sezary syndrome (SS), an aggressive and leukemic form of cutaneous T-cell lymphoma, usually results in shortened survival. Improving innate immunity in SS by targeting natural killer (NK) cells with Toll-like receptor (TLR) agonists could be an interesting modulatory strategy. We evaluated the NK cell populations in SS patients assessing activating and inhibitory receptors expression and profiled the differential expression of TLR signaling pathway genes in unstimulated NK cells and after TLR7/8 stimulation. We observed preserved CD56(bright) NK cells and a low percentage of CD56(dim) NK cells in the peripheral blood of SS patients compared to those in the healthy control group. Both NK cell populations showed down-modulation of NKG2C and NKG2D expression, which was associated with high serum levels of the soluble form of NKG2D ligands. In contrast, an expansion of ""memory"" CD57+ NKG2C+ NK cells and high cytomegalovirus antibody titers were detected in SS patients. Profiling of the TLR signaling genes in NK cells from SS patients showed an abundance of differentially expressed genes (DEGs) in NK cells in the unstimulated condition, with mostly up-regulation of NF kappa B/JNK p38 pathway genes, but there was down-regulation of type I (IFN-alpha/beta) and II (IFN-gamma) interferon and IL-12A. After activation of NK cells with TLR7/8 agonist, the down-regulated genes correlated with the IFN response, and IL-12 became up-regulated, together with other antitumor factors. NK cell activation with a dual agonist for TLR7 and TLR8 is able to induce the expression of IFN-gamma and type I IFN, which can improve immunity in SS patients.
Palavras-chave
Sezary syndrome, natural killer cells, Toll-like receptor 7/8, memory NK cells, differentially expressed genes
URI
https://observatorio.fm.usp.br/handle/OPI/24358
Referências
  1. Bahler DW, 2008, CYTOM PART B-CLIN CY, V74B, P156, DOI 10.1002/cyto.b.20395
  2. Ballanger F, 2009, EXP DERMATOL, V18, P574, DOI 10.1111/j.1600-0625.2008.00817.x
  3. Bath-Hextall FJ, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003412.pub2
  4. Bauernhofer T, 2003, EUR J IMMUNOL, V33, P119, DOI 10.1002/immu.200390014
  5. Beutler B, 2007, IMMUNOL REV, V220, P113, DOI 10.1111/j.1600-065X.2007.00577.x
  6. Bouaziz JD, 2005, J INVEST DERMATOL, V125, P1273, DOI 10.1111/j.0022-202X.2005.23914.x
  7. Burns RP, 2000, CLIN IMMUNOL, V94, P13, DOI 10.1006/clim.1999.4804
  8. Capriotti E, 2008, LEUKEMIA LYMPHOMA, V49, P1190, DOI 10.1080/10428190802064917
  9. Carrel A, 1910, J AMER MED ASSOC, V55, P1379
  10. Cerwenka A, 2016, NAT REV IMMUNOL, V16, P112, DOI 10.1038/nri.2015.9
  11. Cooper MA, 2001, TRENDS IMMUNOL, V22, P633, DOI 10.1016/S1471-4906(01)02060-9
  12. Della Chiesa M, 2013, IMMUNOL LETT, V155, P11, DOI 10.1016/j.imlet.2013.09.020
  13. Dendorfer M, 2003, EUR J DERMATOL, V13, P80
  14. Eisele G, 2006, BRAIN, V129, P2416, DOI 10.1093/brain/awl205
  15. Ghazi B, 2015, J INVEST DERMATOL, V135, P229, DOI 10.1038/jid.2014.286
  16. Groh V, 2002, NATURE, V419, P734, DOI 10.1038/nature01112
  17. Herne KL, 2003, BLOOD, V101, P2132, DOI 10.1182/blood-2002-07-2247
  18. Horwitz SM, 2008, CLIN LYMPHOMA MYELOM, V8, pS187, DOI 10.3816/CLM.2008.s.015
  19. Kared H, 2016, CANCER IMMUNOL IMMUN, V65, P441, DOI 10.1007/s00262-016-1803-z
  20. Kim EJ, 2005, J CLIN INVEST, V115, P798, DOI 10.1172/JCI200524826
  21. Kopp KLM, 2010, LEUKEMIA, V24, P1179, DOI 10.1038/leu.2010.66
  22. Korman N, 2005, ARCH DERMATOL, V141, P467, DOI 10.1001/archderm.141.4.467
  23. Ksienzyk A, 2011, CANCER RES, V71, P6410, DOI 10.1158/0008-5472.CAN-11-1565
  24. LAROCHE L, 1983, J IMMUNOL, V130, P2467
  25. Lebwohl M, 2004, J AM ACAD DERMATOL, V50, P714, DOI 10.1016/j.jaad.2003.12.010
  26. Lee J, 2003, P NATL ACAD SCI USA, V100, P6646, DOI 10.1073/pnas.0631696100
  27. Lee JC, 2004, J IMMUNOL, V172, P7335
  28. Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
  29. Lopez-Verges S, 2010, BLOOD, V116, P3865, DOI 10.1182/blood-2010-04-282301
  30. Ma XR, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.22647
  31. Manfrere KCG, 2016, ONCOTARGET, V7, P74592, DOI 10.18632/oncotarget.12816
  32. Moretta L, 2010, BLOOD, V116, P3689, DOI 10.1182/blood-2010-09-303057
  33. Nielsen CM, 2015, J IMMUNOL, V194, P4657, DOI 10.4049/jimmunol.1403080
  34. Olsen E, 2007, BLOOD, V110, P1713, DOI 10.1182/blood-2007-03-055749
  35. Orange JS, 2013, J ALLERGY CLIN IMMUN, V132, P515, DOI 10.1016/j.jaci.2013.07.020
  36. Parodi M, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1052353
  37. Peres K, 2003, EUR J DERMATOL, V13, P413
  38. Peris K, 2003, EUR J DERMATOL, V13, P5
  39. Rolle A, 2014, J CLIN INVEST, V124, P5305, DOI 10.1172/JCI77440
  40. ROOK AH, 1995, HEMATOL ONCOL CLIN N, V9, P997
  41. ROOK AH, 1993, ARCH DERMATOL, V129, P486, DOI 10.1001/archderm.129.4.486
  42. Rook AH, 2015, BLOOD, V126, P1452, DOI 10.1182/blood-2015-02-630335
  43. Sanchez-Correa B, 2016, CANCER IMMUNOL IMMUN, V65, P453, DOI 10.1007/s00262-015-1720-6
  44. Schon MP, 2008, ONCOGENE, V27, P190, DOI 10.1038/sj.onc.1210913
  45. Schulze HJ, 2005, BRIT J DERMATOL, V152, P939, DOI 10.1111/j.1365-2133.2005.06486.x
  46. SIDKY YA, 1992, CANCER RES, V52, P3528
  47. Spaccarelli N, 2015, DERMATOL CLIN, V33, P731, DOI 10.1016/j.det.2015.05.008
  48. Steinmann A, 2000, J AM ACAD DERMATOL, V43, P555, DOI 10.1067/mjd.2000.107954
  49. Stockfleth E, 2001, BRIT J DERMATOL, V144, P1050, DOI 10.1046/j.1365-2133.2001.04197.x
  50. Su MW, 2003, CANCER RES, V63, P7122
  51. Su SA, 2017, ONCOTARGET, V8, P25700, DOI 10.18632/oncotarget.14878
  52. Suchin KR, 2002, ARCH DERMATOL, V138, P1137, DOI 10.1001/archderm.138.9.1137
  53. Tomai MA, 2007, EXPERT REV VACCINES, V6, P835, DOI 10.1586/14760584.6-5.835
  54. Tracey L, 2003, BLOOD, V102, P1042, DOI 10.1182/blood-2002-11-3574
  55. Umezu T, 2013, ONCOGENE, V32, P2747, DOI 10.1038/onc.2012.295
  56. Vasilakos JP, 2013, EXPERT REV VACCINES, V12, P809, DOI 10.1586/14760584.2013.811208
  57. Vivier E, 2002, CURR OPIN IMMUNOL, V14, P306, DOI 10.1016/S0952-7915(02)00337-0
  58. VOWELS BR, 1992, J INVEST DERMATOL, V99, P90, DOI 10.1111/1523-1747.ep12611877
  59. Wagner TL, 1997, CYTOKINE, V9, P837, DOI 10.1006/cyto.1997.0239
  60. WOOD GS, 1991, AM J PATHOL, V138, P1545
  61. Wysocka M, 2004, BLOOD, V104, P4142, DOI 10.1182/blood-2004-03-1190
  62. Wysocka M, 2011, LEUKEMIA LYMPHOMA, V52, P1970, DOI 10.3109/10428194.2011.582202
  63. Yoo EK, 2001, J AM ACAD DERMATOL, V45, P208, DOI 10.1067/mjd.2001.116345
  64. Zeitouni NC, 2005, BRIT J DERMATOL, V152, P376, DOI 10.1111/j.1365-2133.2005.06307.x

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPT
Artigos e Materiais de Revistas Científicas - FM/MDT
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/53
Artigos e Materiais de Revistas Científicas - LIM/56
Artigos e Materiais de Revistas Científicas - ODS/03